Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months

Vecchioli-Scaldazza, Carlo; Morosetti, Carolina

doi:10.1590/s1677-5538.ibju.2016.0611

Cited by 27 publications

(18 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The largest study with 105 women with OAB compared solifenacin alone with PTNS alone with solifenacin and PTNS combined [14]. Results demonstrated that PTNS was more effective than solifenacin, but that combination therapy was the most effective and demonstrated more durability than PTNS and solifenacin alone.…”

Section: Ptns and Anti-muscarinic Treatmentmentioning

confidence: 99%

Posterior tibial nerve stimulation for overactive bladder—techniques and efficacy

et al. 2019

View full text Add to dashboard Cite

The ideal treatment for overactive bladder is still elusive. In those where medication fails to improve symptoms options include invasive treatments such as botulinum toxin-A, sacral neural stimulation or posterior tibial nerve stimulation. Scientific professional society guidelines advise percutaneous posterior tibial nerve stimulation as a third line treatment option only after multidisciplinary team review as well as failure of both conservative and pharmacological management. The aim of this article is to review all techniques for tibial nerve stimulation and their efficacy.

show abstract

Section: Ptns and Anti-muscarinic Treatmentmentioning

confidence: 99%

Posterior tibial nerve stimulation for overactive bladder—techniques and efficacy

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Four prospective studies have evaluated percutaneous tibial nerve stimulation (PTNS) in combination with anticholinergic medications (either tolterodine or solifenacin; Table ) . All four studies include fewer than 40 patients, though universally report that combination therapy improves urinary frequency, urgency, and urge incontinence outcomes compared to either anticholinergic monotherapy or PTNS monotherapy.…”

Section: Resultsmentioning

confidence: 99%

Section: Posterior Tibial Nerve Stimulation With Medicationsmentioning

confidence: 99%

Combination therapy in overactive bladder‐untapped research opportunities: A systematic review of the literature

Kasman

Stave

Elliott

2019

Neurourology and Urodynamics

View full text Add to dashboard Cite

Aims Overactive bladder (OAB) affects over 17% of the population and significantly effect the health‐related quality of life. The treatments for OAB include first line (lifestyle modification, pelvic floor muscle training), second line (anticholinergic or beta‐3 agonist medications), and third line therapies (intradetrusor botulinum toxin injection, sacral neurostimulation [SNM], or percutaneous tibial nerve stimulation [PTNS]). For those with urinary incontinence secondary to OAB, complete continence is the goal of therapy, though cure rates are only 5% to 40%. The use of combination therapies can be employed in refractory OAB, however, the efficacy of pooled modalities is relatively unknown. Our objective was to determine the volume of data supporting combination therapy in treating OAB. Methods We systematically reviewed PubMed, EMBASE, the Cochrane Library, and Google Scholar for articles published before October 2018. Each was independently reviewed by two reviewers and examined in detail if they met inclusion criteria. Results A total of 32 studies met inclusion criteria and were reviewed. Most large prospective studies evaluated combinations of medications with behavioral therapy or medications together. Combination therapy studies of third‐line treatments were rare and centered on medication with PTNS. No studies examined intradetrusor botulinum toxin injections in combination with another therapy and only one retrospective study briefly examined SNM therapy in combination with medication. Conclusion Combination therapy, with certain first, second, and third‐line OAB therapies, appears to be efficacious. There is a further need for carefully designed combination therapy studies, particularly those including third line modalities.

show abstract

Section: Ptnsmentioning

confidence: 99%

“…They found no statistical differences between solifenacin and PTNS group in terms of daily and night time micturiction frequency, urgency, urgency incontinence, and quality of life; on the contrary, they found a significant difference between the combination therapy group and the other two in all aforementioned domains (all p < 0.05). 32 In a large prospective cohort of 200 patients, Del Río-Gonzales et al evaluated the durability of PTNS. They demonstrated the efficacy of PTNS with a success rate of 73.5% and a symptom improvement in 20.5%; 90.5% of patients reached a clinical improvement >50%.…”

Section: Ptnsmentioning

confidence: 99%

Neuromodulation in urology, state of the art

Ammirati¹,

Giammò²,

Manassero³

et al. 2019

Urologia Journal

View full text Add to dashboard Cite

Sacral neuromodulation is an approved and validated treatment for overactive bladder syndrome, chronic non-obstructive retention, and chronic pelvic pain. Percutaneous tibial nerve stimulation is a less invasive approach of neuromodulation. We performed a literature research to assess the current evidence available about neuromodulation. Both techniques appear to be effective and safe third-line treatments. The overall success rate ranges from 43% to 85% for sacral neuromodulation and from 40% to 79.5% for percutaneous tibial nerve stimulation. Sacral neuromodulation has a higher incidence of complications in comparison to percutaneous tibial nerve stimulation, due to the more invasive surgical technique and the presence of a permanent implant. The incidence of surgical revision ranges between 9% and 33%. The most frequent complication with sacral neuromodulation is pain at implant site (15%–42%), followed by lead migration (4%–21%), pain at lead site (5.4%–19.1%), leg pain (18%), and infection (5.7%–6.1%). The quality of the studies on sacral neuromodulation and percutaneous tibial nerve stimulation in literature is quite modest, because of the shortage of good randomized clinical trial; most of the studies are prospective observational studies with mid-term follow-up.

show abstract

Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months

Cited by 27 publications

References 17 publications

Posterior tibial nerve stimulation for overactive bladder—techniques and efficacy

Posterior tibial nerve stimulation for overactive bladder—techniques and efficacy

Combination therapy in overactive bladder‐untapped research opportunities: A systematic review of the literature

Neuromodulation in urology, state of the art

Contact Info

Product

Resources

About